Measuring blood parameters noninvasively in patients is of great importance in many clinical applications. During the course of our research in an ERC-funded project, in which light is used to image and threat cancer, we have disc...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
COMMITMENT
Combined Molecular Microscopy for Therapy and Personalized M...
8M€
Cerrado
SPCCT
In Vivo Spectral Photon Counting CT Molecular Imaging in Car...
6M€
Cerrado
MIVFC
Development of a multichannel in vivo flow cytometer for the...
50K€
Cerrado
PTA2015-11242-I
Técnico Superior de Citometría de Flujo para la Unidad de Mi...
39K€
Cerrado
EQC2019-006148-P
Adquisición de un citómetro analizador espectral
110K€
Cerrado
MicroflowLife
Whole-organ 3D ultrasound micro-flow imaging: from basics ph...
2M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Measuring blood parameters noninvasively in patients is of great importance in many clinical applications. During the course of our research in an ERC-funded project, in which light is used to image and threat cancer, we have discovered that the minimally invasive imaging technique we have been developing, termed spectrally encoded endoscopy, is extremely effective for imaging flowing blood cells without the need for mechanical scanning. We have shown that this technique, termed spectrally encoded flow cytometry (SEFC), is capable of subsurface confocal imaging at sub-micron resolutions, at speeds that are sufficient for the detection of rapid capillary flow. Being able to image microscopic cellular features in patients without pain, stress, timely analysis and risk of infection, this technique represents an uncharted territory in medical diagnosis, and would have a wide variety of applications in routine care, intensive care and in the operating room. During the twelve months of the requested fund, we plan to complete a system prototype for future pre-clinical and clinical tests and establish a feasible business plan for further commercialization of the technology.